참고문헌
- Beuselinck B, Vano YA, Oudard S, et al (2014). Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int, 114, 81-9. https://doi.org/10.1111/bju.12494
- Bromwich E, McMillan DC, Lamb GW, Vasey PA, Atchison M (2004). The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer, 91, 1236-8. https://doi.org/10.1038/sj.bjc.6602152
- Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75. https://doi.org/10.7314/APJCP.2014.15.8.3369
- Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5. https://doi.org/10.7314/APJCP.2013.14.3.2101
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004). Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable nonsmall- cell lung cancer. Br J Cancer, 90, 1704-6.
- Fujita T, Iwamura M, Ishii D, et al (2012). C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol, 19, 908-13. https://doi.org/10.1111/j.1442-2042.2012.03071.x
- Gore ME, Szczylik C, Porta C, et al (2009). Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expandedaccess trial. Lancet Oncol, 10, 757-63. https://doi.org/10.1016/S1470-2045(09)70162-7
- Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H (2014). Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev, 15, 3801-4. https://doi.org/10.7314/APJCP.2014.15.8.3801
- Heng DY, Xie W, Regan MM, et al (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol, 27, 5794-9. https://doi.org/10.1200/JCO.2008.21.4809
- Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML (2001). Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene, 20, 198-208. https://doi.org/10.1038/sj.onc.1204076
- Karakiewicz PI, Hutterer GC, Trinh QD, et al (2007). C-reactive protein is an informative predictor of renal cell carcinomaspecific mortality: a European study of 313 patients. Cancer, 110, 1241-7. https://doi.org/10.1002/cncr.22896
- Kawashima A, Tsujimura A, Takayama H, et al (2012). Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. Int J Urol, 19, 1050-7; author reply 1058-9. https://doi.org/10.1111/j.1442-2042.2012.03115.x
- Kinoshita T, Ito H, Miki C (1999). Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer, 85, 2526-31. https://doi.org/10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3
- McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC (2004). The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer, 91, 1993-5. https://doi.org/10.1038/sj.bjc.6602248
- McMillan DC, Scott HR, Watson WS, et al (1998). Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer, 31, 101-5. https://doi.org/10.1080/01635589809514687
- Miyake H, Miyazaki A, Harada K, Fujisawa (2014). Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol, 31, 978. https://doi.org/10.1007/s12032-014-0978-4
- Motzer RJ, Bacik J, Mazumdar M (2004). Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res, 10, 6302-3. https://doi.org/10.1158/1078-0432.CCR-040031
- Motzer RJ, Hutson TE, Tomczak P, et al (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 3584-90. https://doi.org/10.1200/JCO.2008.20.1293
- Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. https://doi.org/10.1056/NEJMoa065044
- Motzer RJ, Michaelson MD, Redman BG, et al (2006a). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24. https://doi.org/10.1200/JCO.2005.02.2574
- Motzer RJ, Rini BI, Bukowski RM, et al (2006b). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24. https://doi.org/10.1001/jama.295.21.2516
- Naito S, Yamamoto N, Takayama T, et al (2010). Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol, 57, 317-25. https://doi.org/10.1016/j.eururo.2008.12.026
- Rini BI, Atkins MB (2009). Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol, 10, 992-1000. https://doi.org/10.1016/S1470-2045(09)70240-2
- Rini BI, Cohen DP, Lu DR, et al (2011). Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 103, 763-73. https://doi.org/10.1093/jnci/djr128
- Schmidinger M, Vogl UM, Bojic M, et al (2011). Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer, 117, 534-44. https://doi.org/10.1002/cncr.25422
- Scott HR, McMillan DC, Forrest LM, et al (2002). The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer, 87, 264-7. https://doi.org/10.1038/sj.bjc.6600466
- Tomita Y, Shinohara N, Yuasa T, et al (2010). Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol, 40, 1166-72. https://doi.org/10.1093/jjco/hyq146
- Trikha M, Corringham R, Klein B, Rossi JF (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res, 9, 4653-65.
- Uemura H, Shinohara N, Yuasa T, et al (2010). A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol, 40, 194-202. https://doi.org/10.1093/jjco/hyp146
피인용 문헌
- Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma vol.17, pp.1, 2017, https://doi.org/10.1186/s12894-017-0267-6
- Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma vol.36, pp.1, 2017, https://doi.org/10.1186/s40880-017-0214-7
- Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors vol.49, pp.3, 2017, https://doi.org/10.1007/s11255-017-1502-5
- Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan pp.09198172, 2019, https://doi.org/10.1111/iju.13830
- Role of systemic inflammatory response markers in urological malignancy pp.09198172, 2019, https://doi.org/10.1111/iju.13801